PL 9643
Alternative Names: PL-9643Latest Information Update: 14 May 2025
At a glance
- Originator Palatin Technologies
- Class Anti-inflammatories; Eye disorder therapies; Peptides
- Mechanism of Action Melanocortin type 1 receptor agonists; Melanocortin type 5 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase III Dry eyes
- Preclinical Diabetic retinopathy; Retinal disorders
Most Recent Events
- 29 Apr 2025 Palatin Technologies plans a phase III MELODY-2 in Dry eyes in the second half of 2025 (Ophthalmic)
- 29 Apr 2025 Palatin Technologies plans a phase III MELODY-3 trials in Dry eyes in the second half of 2025(Ophthalmic)
- 28 Aug 2024 Palatin Technologies concluded a positive Type C meeting with the FDA and agreement on the two phase III MELODY-2 and MELODY-3 trials protocols, including the sign and symptom endpoints for PL 9643 for Dry eye disease (DED)